A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: A GOELAMS study

Leukemia

Volumn 25, Issue 6, 2011, Pages 939-944

  Chevallier, P ^a,i   Labopin, M ^b   Turlure, P ^c   Prebet, T ^d   Pigneux, A ^e   Hunault, M ^f   Filanovsky, K ^g   Cornillet Lefebvre, P ^h   Luquet, I ^h   Lode, L ⁱ   Richebourg, S ⁱ   Blanchet, O ^f   Gachard, N ^c   Vey, N ^d   Ifrah, N ^f   Milpied, N ^e   Harousseau, J L ^a   Bene, M C ^j   Mohty, M ^a   Delaunay, J ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g KAPLAN MEDICAL CENTER   (Israel)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

AML; FLT3; NPM1; refractory; relapse; score

Indexed keywords

GEMTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

EID: 79958108730     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.25     Document Type: Article

References (18)

1. Löwenberg B, Downing J, Burnett A. Acute myeloid leukemia, review article. N Engl J Med 1999; 341: 1051-1062. (Pubitemid 29451802)
2. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky C, Craddock C et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135: 450-474. (Pubitemid 44596187)
3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010; 115: 453-474.
4. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinberg E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099. (Pubitemid 44154650)
5. Breems DA, Van Putten W, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognosis index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969-1978. (Pubitemid 46211376)
6. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18-34. (Pubitemid 40524048)
7. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long-term disease-free survival after Gemtuzumab, intermediate-dose cytarabine and Mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukaemia. J Clin Oncol 2008; 26: 5192-5197.
8. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including Gemtuzumab Ozogamicin. Leukemia 2010; 24: 467-469.
9. Filanovski K, Shvidel L, Shtalrid M. Advantage of MIDAM protocol in treatment of the elderly patients with refractory and relapsing acute myeloid leukemia. J Clin Oncol 2010; 28: e115.
10. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618-3620. (Pubitemid 41609201)
11. Kiyoi H, Naoe T, Yokota S, Hamagushi M, Ohno R, Saito H et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 1447-1452. (Pubitemid 27404383)
12. Lioure B, Delaunay J, Blaise D, Milpied N, Guardiola P, Cahn JY et al. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukemia (AML) in 1st CR: first results of the AML .2001. trial. Blood (ASH Annual Meeting Abstracts) 2006; 108, abstract 319.
13. Chevallier P, Fornecker L, Lioure B, Bene MC, Pigneux A, Recher C et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24: 1380-1385.
14. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W et al. Validation of the European Prognosis Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 2006; 134: 58-60. (Pubitemid 43830028)
15. Clarke WT, Marks PW. Gemtuzumab Ozogamicin: is there room for salvage? Blood 2010; 116: 2618-2619.
16. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of Gemtuzumab Ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2010; 29: 369-377.
17. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate-use of sorafenib in Flt3-ITD positive acute myeloid leukemia: sustained regression prior and post-allogeneic stem cell transplantation. Blood 2009; 113: 6567-6571.
18. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.